Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2017 Jul-Aug;92(4):591-593.
doi: 10.1590/abd1806-4841.20176481.

Biologic therapy-induced pemphigus

Marina Zoega Hayashida  1 , Jhonatan Rafael Siqueira Pinheiro  1 , Milvia Maria Simões E Silva Enokihara  2 , Mônica Ribeiro de Azevedo Vasconcellos  1
Affiliations
Case Reports

Biologic therapy-induced pemphigus

Marina Zoega Hayashida et al. An Bras Dermatol. 2017 Jul-Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of interests: None.

Figures

Figure 1
Figure 1
A) Erythematous scaly papules and plaques, with some superficial ulcerations on the neckline; B) Improvement after treatment.
Figure 2
Figure 2
A) Focal area with suprabasal acantholysis, involving the follicular epithelium, besides acanthosis and crust with fibrin and leukocytes (HE, X100); B) Immunohistochemistry with expression of intercellular IgG; C) Immunohistochemistry with expression of intercellular C3.
See this image and copyright information in PMC

References

    1. Brenner S, Goldberg I. Drug-induced pemphigus. Clin Dermatol. 2011;29:455–457. - PubMed
    1. Landau M, Brenner S. Histopathologic findings in drug-induced pemphigus. Am J Dermatopathol. 1997;19:411–414. - PubMed
    1. Baroni A, Russo T, Faccenda F, Piccolo V. Amoxicillin/Clavulanic Acid-Induced Pemphigus Vulgaris: Case Report. Acta Dermatovenerol Croat. 2012;20:108–111. - PubMed
    1. Genovese MC, Greenwald MW, Cho CS, Berman A, Jin L, Cameron G. A Phase 2 Study of Multiple Subcutaneous Doses of LY2439821, An Anti-IL-17 Monoclonal Antibody, in Patients with Rheumatoid Arthritis in Two Populations: Naïve to Biologic Therapy or Inadequate Responders to Tumor Necrosis Factor Alpha Inhibitors; ACR meeting; Chicago. 2011.
    1. Cosentyx (secukinumab) [prescribing information] East Hanover, NJ: Novartis Pharmaceuticals Corp; 2016.

LinkOut - more resources